title: Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission.
authors.forename: Jan
authors.initials: J
authors.lastname: Václavík
authors.forename: Tomás
authors.initials: T
authors.lastname: Szotkowski
authors.forename: Martin
authors.initials: M
authors.lastname: Hutyra
authors.forename: Jirí
authors.initials: J
authors.lastname: Kozák
authors.forename: Jan
authors.initials: J
authors.lastname: Lukl
authors.forename: Milos
authors.initials: M
authors.lastname: Táborský
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D001549:Benzamides; D004359:Drug Therapy, Combination; D004696:Endocarditis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004804:Eosinophils / Q000502:physiology*; D006321:Heart / Q000503:physiopathology*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000068877:Imatinib Mesylate; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000378:metabolism*; D012074:Remission Induction; D013927:Thrombosis / Q000209:etiology; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use; D039221:mRNA Cleavage and Polyadenylation Factors / Q000378:metabolism*
chemical_list: D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D014859:Warfarin; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha; D011241:Prednisone